Dr. Neda Moatamed studies immune checkpoint regulator expression for selection of targeted therapy in neoplasms of the female reproductive organs and breast. She was the first to report EGFR deletions in lobular carcinomas of the breast. Dr. Moatamed is a respected mentor who always includes trainees in her projects. In 2017, the UCLA trainees gave her the inaugural Mentor award.


